QuantaLife, a US-based technology company for human genomics, has raised $17.2m in its series B round from a consortium including Mérieux Développement, the corporate venturing company of Institut Mérieux, a French industrial holding company.

Venture capital firm Paladin Capital Group led the round, and was joined by peer Vital Financial, as well as Mérieux. Paladin had provided an undisclosed sum in QuantaLife’s A round.

Francois Valencony, managing director of Merieux Developpement, which plans to invest €70m as a minority shareholder in deals by 2013, said: "QuantaLife’s technology is very compelling and represents a unique opportunity to establish a new standard for the future of genomics research and nucleic acid testing, with a simple, reliable and cost- effective solution."

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?